# Characterizing molecular phenotypes of pancreatic islet reactive B cells in T1D through single cell sequencing

> **NIH NIH F31** · UNIVERSITY OF COLORADO DENVER · 2023 · $36,354

## Abstract

Project Summary
High affinity pancreatic islet-reactive B cells contribute to young onset type 1 diabetes (T1D) disease
progression, but are rare in the peripheral blood, and therefore, difficult to study. Hence, little is known regarding
the phenotype and function of diabetogenic B cells in T1D. Recent developments in single cell RNA sequencing
methods have enabled simultaneous collection of gene expression, B and T cell receptor (BCR/TCR) V(D)J
clonotype, protein expression (CITE-seq), and functional data from single cells. We have developed a method
called AVID-seq (Antigen Reactivity and V(D)J In Droplets by Sequencing) to enable detection and
characterization of relevant antigen-binding cells from polyclonal repertoires that can be multiplexed using
standard single cell droplet sequencing methods. We hypothesize that, unlike healthy control subjects,
young onset T1D subjects will exhibit a loss of anergic islet-reactive B cells and a corresponding
increase in activated, high affinity, effector-like islet-reactive B cells in their peripheral blood. Aim 1 will
analyze islet-reactive B cells (i.e. insulin, GAD65, IA-2, and ZnT8) from the peripheral blood of young new-onset
T1D and age/sex matched healthy controls using AVID-seq. It is expected that differential gene expression,
surface protein expression (CITE-Seq), and V(D)J sequence characteristics will identify an activated B cell
phenotype that is expanded in T1D donors, which likely contributes to disease. Aim 2 will determine the
relationship between B cell receptor (BCR)-antigen affinity and normalized counts of antigen bound per cell, as
determined by AVID-seq. This aim has the potential to significantly streamline current methods to determine
BCR-antigen affinities and discriminate pathogenic high affinity B cells from low affinity, likely non-pathogenic, B
cells. The potential impact of these studies lies in identification of the pathogenic B cells involved in young onset
T1D, which will inform future age-appropriate therapeutics. Along with these proposed studies, the applicant has
assembled a diverse team of experts to serve on her advisory committee, a comprehensive training and
development plan that is tailored to her needs, and a research environment that will foster her growth as a
predoctoral student.

## Key facts

- **NIH application ID:** 10600510
- **Project number:** 1F31DK134095-01A1
- **Recipient organization:** UNIVERSITY OF COLORADO DENVER
- **Principal Investigator:** Catherine A Nicholas
- **Activity code:** F31 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $36,354
- **Award type:** 1
- **Project period:** 2023-03-01 → 2026-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10600510

## Citation

> US National Institutes of Health, RePORTER application 10600510, Characterizing molecular phenotypes of pancreatic islet reactive B cells in T1D through single cell sequencing (1F31DK134095-01A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10600510. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*